Literature DB >> 9950264

Aurintricarboxylic acid inhibits apoptosis and supports proliferation in a haemopoietic growth-factor dependent myeloid cell line.

D J Andrew1, A W Hay, S W Evans.   

Abstract

The actions of the nuclease inhibitor aurintricarboxylic acid (ATA) were investigated in the growth-factor dependent murine myeloid cell line NSF-60. NSF-60 cells proliferate in response to interleukin-3 (IL-3) and undergo apoptosis when deprived of exogenous IL-3, as demonstrated by the appearance of characteristic DNA 'ladders' following agarose gel electrophoresis. ATA, at concentrations between 5 and 25 microM, inhibited apoptosis in growth-factor deprived cells as demonstrated by inhibition of DNA fragmentation and increased cell survival. ATA at a concentration of 25 microM supported proliferation of the cell line in the absence of exogenous growth-factor. Both ATA and IL-3 increased protein phosphorylation in this cell line. ATA and IL-3 induced proliferation was inhibited by the kinase inhibitors genistein, staurosporine and H-7. These findings suggest that, in NSF-60, ATA is not acting exclusively as an endonuclease inhibitor and that protein phosphorylation is involved in the mechanism of action of ATA in this cell line.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950264     DOI: 10.1016/s0162-3109(98)00049-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  6 in total

1.  Inhibition of cytokine-induced JAK-STAT signalling pathways by an endonuclease inhibitor aurintricarboxylic acid.

Authors:  Ching-Wen Chen; Yee Chao; Ying-Hsin Chang; Ming-Jen Hsu; Wan-Wan Lin
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

2.  Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay.

Authors:  Sergio Hernández; Mikael Feracci; Carolina Trajano De Jesus; Priscila El Kazzi; Rafik Kaci; Laura Garlatti; Clemence Mondielli; Fabrice Bailly; Philippe Cotelle; Franck Touret; Xavier de Lamballerie; Bruno Coutard; Etienne Decroly; Bruno Canard; François Ferron; Karine Alvarez
Journal:  Antiviral Res       Date:  2022-06-16       Impact factor: 10.103

3.  Extracellular control of intracellular drug release for enhanced safety of anti-cancer chemotherapy.

Authors:  Qian Zhu; Haixia Qi; Ziyan Long; Shang Liu; Zhen Huang; Junfeng Zhang; Chunming Wang; Lei Dong
Journal:  Sci Rep       Date:  2016-06-23       Impact factor: 4.379

4.  Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer.

Authors:  Nadiya Druzhyna; Bartosz Szczesny; Gabor Olah; Katalin Módis; Antonia Asimakopoulou; Athanasia Pavlidou; Petra Szoleczky; Domokos Gerö; Kazunori Yanagi; Gabor Törö; Isabel López-García; Vassilios Myrianthopoulos; Emmanuel Mikros; John R Zatarain; Celia Chao; Andreas Papapetropoulos; Mark R Hellmich; Csaba Szabo
Journal:  Pharmacol Res       Date:  2016-08-10       Impact factor: 7.658

5.  Inhibition of enterovirus 71 replication and the viral 3D polymerase by aurintricarboxylic acid.

Authors:  Hui-Chen Hung; Tzu-Chun Chen; Ming-Yu Fang; Kuei-Jung Yen; Shin-Ru Shih; John T-A Hsu; Ching-Ping Tseng
Journal:  J Antimicrob Chemother       Date:  2010-01-20       Impact factor: 5.790

6.  Aurintricarboxylic acid inhibits influenza virus neuraminidase.

Authors:  Hui-Chen Hung; Ching-Ping Tseng; Jinn-Moon Yang; Yi-Wei Ju; Sung-Nain Tseng; Yen-Fu Chen; Yu-Sheng Chao; Hsing-Pang Hsieh; Shin-Ru Shih; John T-A Hsu
Journal:  Antiviral Res       Date:  2008-11-17       Impact factor: 5.970

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.